Elimination of chronic viral infection by blocking CD27 signaling

Journal of Experimental Medicine

Volumn 203, Issue 9, 2006, Pages 2145-2155

  Matter, Matthias ^a   Odermatt, Bernhard ^b   Yagita, Hideo ^c   Nuoffer, Jean Marc ^a   Ochsenbein, Adrian F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD70 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; HEPATITIS C VIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; VIRUS INFECTION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD; ANTIGENS, CD27; ANTIGENS, CD70; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSION; INTERFERON TYPE II; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; NEUTRALIZATION TESTS; SIGNAL TRANSDUCTION; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 33748462545     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20060651     Document Type: Article

References (52)

1. Bertoletti, A., A. Sette, F.V. Chisari, A. Penna, M. Levrero, and M. De Carli. 1994. Natural variants of cytotoxic epitopes are T cells receptor antagonists for anti-viral cytotoxic T cells. Nature. 369:407-410.
2. Ciurea, A., P. Klenerman, L. Hunziker, E. Horvath, B.M. Senn, A.F. Ochsenbein, H. Hengartner, and R.M. Zinkernagel. 2000. Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc. Natl. Acad. Sci. USA. 97:2749-2754.
3. Phillips, R.E., S. Rowland-Jones, D.F. Nixon, F.M. Gotch, J.P. Edwards, A.O. Ogunlesi, J.G. Elvin, J.A. Rothbard, C.R. Bangham, C.R. Rizza, et al. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 354:453-459.
4. Wei, X., J.M. Decker, S. Wang, H. Hui, J.C. Kappes, X. Wu, J.F. Salazar-Gonzalez, M.G. Salazar, J.M. Kilby, M.S. Saag, et al. 2003. Antibody neutralization and escape by HIV-1. Nature. 422:307-312.
5. Lane, H.C., J.M. Depper, W.C. Greene, G. Whalen, T.A. Waldmann, and A.S. Fauci. 1985. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N. Engl. J. Med. 313:79-84.
6. Pilgrim, A.K., G. Pantaleo, O.J. Cohen, L.M. Fink, J.Y. Zhou, J.T. Zhou, D.P. Bolognesi, A.S. Fauci, and D.C. Montefiori. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176:924-932.
7. Netski, D.M., T. Mosbruger, E. Depla, G. Maertens, S.C. Ray, R.G. Hamilton, S. Roundtree, D.L. Thomas, J. McKeating, and A. Cox. 2005. Humoral immune response in acute hepatitis C virus infection. Clin. Infect. Dis. 41:667-675.
8. Odermatt, B., M. Eppler, T.P. Leist, H. Hengartner, and R.M. Zinkernagel. 1991. Virus-triggered acquired immunodeficiency by cytotoxic T-cell- dependent destruction of antigen-presenting cells and lymph follicle structure. Proc. Natl. Acad. Sci. USA. 88:8252-8256.
9. Battegay, M., D. Moskophidis, H. Waldner, M.A. Brundler, W.-P. Fung-Leung, T.W. Mak, H. Hengartner, and R.M. Zinkernagel. 1993. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells. J. Immunol. 151:5408-5415.
10. Hangartner, L., B.M. Senn, B. Ledermann, U. Kalinke, P. Seiler, E. Bucher, R.M. Zellweger, K. Fink, B. Odermatt, K. Burki, et al. 2003. Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 100:12883-12888.
11. Kwong, P.D. 2005. Human immunodeficiency virus: refolding the envelope. Nature. 433:815-816.
12. Pinschewer, D.D., M. Perez, E. Jeetendra, T. Bachi, E. Horvath, H. Hengartner, M.A. Whitt, J.C. de la Torre, and R.M. Zinkernagel. 2004. Kinetics of protective antibodies are determined by the viral surface antigen. J. Clin. Invest. 114:988-993.
13. Planz, O., S. Ehl, E. Furrer, E. Horvath, M.A. Brundler, H. Hengartner, and R.M. Zinkernagel. 1997. A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc. Natl. Acad. Sci. USA. 94:6874-6879.
14. Borst, J., J. Hendriks, and Y. Xiao. 2005. CD27 and CD70 in T cell and B cell activation. Curr. Opin. Immunol. 17:275-281.
15. Akiba, H., H. Nakano, S. Nishinaka, M. Shindo, T. Kobata, M. Atsuta, C. Morimoto, C.F. Ware, N.L. Malinin, D. Wallach, et al. 1998. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J. Biol. Chem. 273:13353-13358.
16. Tesselaar, K., R. Arens, G.M. van Schijndel, P.A. Baars, M.A. van der Valk, J. Borst, M.H. van Oers, and R.A. van Lier. 2003. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat. Immunol. 4:49-54.
17. Hazenberg, M.D., S.A. Otto, B.H. van Benthem, M.T. Roos, R.A. Coutinho, J.M. Lange, D. Hamann, M. Prins, and F. Miedema. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 17:1881-1888.
18. De Milito, A., A. Nilsson, K. Titanji, R. Thorstensson, E. Reizenstein, M. Narita, S. Grutzmeier, A. Sonnerborg, and F. Chiodi. 2004. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood. 103:2180-2186.
19. Xiao, Y., J. Hendriks, P. Langerak, H. Jacobs, and J. Borst. 2004. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J. Immunol. 172:7432-7441.
20. Hunziker, L., M. Recher, A.J. Macpherson, A. Ciurea, S. Freigang, H. Hengartner, and R.M. Zinkernagel. 2003. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat. Immunol. 4:343-349.
21. Recher, M., K.S. Lang, L. Hunziker, S. Freigang, B. Eschli, N.L. Harris, A. Navarini, B.M. Senn, K. Fink, M. Lotscher, et al. 2004. Deliberate removal of T cell help improves virus-neutralizing antibody production. Nat. Immunol. 5:934-942.
22. Matter, M., S. Mumprecht, D.D. Pinschewer, V. Pavelic, H. Yagita, S. Krautwald, J. Borst, and A.F. Ochsenbein. 2005. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. Eur. J. Immunol. 35:3229-3239.
23. Karrer, U., A. Althage, B. Odermatt, C.W.M. Roberts, S. Korsmeyer, S. Miyawaki, H. Hengartner, and R.M. Zinkernagel. 1997. On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11-/-) mutant mice. J. Exp. Med. 185:2157-2170.
24. Arens, R., K. Tesselaar, P.A. Baars, G.M. van Schijndel, J. Hendriks, S.T. Pals, P. Krimpenfort, J. Borst, M.H. van Oers, and R.A. van Lier. 2001. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity. 15:801-812.
25. Arens, R., M.A. Nolte, K. Tesselaar, B. Heemskerk, K.A. Reedquist, R.A. van Lier, and M.H. van Oers. 2004. Signaling through CD70 regulates B cell activation and IgG production. J. Immunol. 173:3901-3908.
26. Kobata, T., S. Jacquot, S. Kozlowski, K. Agematsu, S.F. Schlossman, and C. Morimoto. 1995. CD27-CD70 interactions regulate B-cell activation by T cells. Proc. Natl. Acad. Sci. USA. 92:11249-11253.
27. Roost, H., S. Charan, R. Gobet, E. Rüedi, H. Hengartner, A. Althage, and R.M. Zinkernagel. 1988. An acquired immune suppression in mice caused by infection with lymphocytic choriomeningitis virus. Eur. J. Immunol. 18:511-518.
28. Senn, B.M., C. Lopez-Macias, U. Kalinke, A. Lamarre, A. Isibasi, R.M. Zinkernagel, and H. Hengartner. 2003. Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity to mount protective antibody responses against pathogen infections. Eur. J. Immunol. 33:950-961.
29. Moskophidis, D., F. Lechner, H. Pircher, and R.M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 362:758-761.
30. Oshima, H., H. Nakano, C. Nohara, T. Kobata, A. Nakajima, N.A. Jenkins, D.J. Gilbert, N.G. Copeland, T. Muto, H. Yagita, and K. Okumura. 1998. Characterization of murine CD70 by molecular cloning and mAb. Int. Immunol. 10:517-526.
31. Oxenius, A., R.M. Zinkernagel, and H. Hengartner. 1998. Comparison of activation versus induction of unresponsiveness of virus- specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. Immunity. 9:449-457.
32. Burton, D.R., R.C. Desrosiers, R.W. Doms, W.C. Koff, P.D. Kwong, J.P. Moore, G.J. Nabel, J. Sodroski, I.A. Wilson, and R.T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
33. Ochsenbein, A.F., and R.M. Zinkernagel. 2000. Natural antibodies and complement link innate and acquired immunity. Immunol. Today. 21:624-630.
34. Pillai, S., A. Cariappa, and S.T. Moran. 2005. Marginal zone B cells. Annu. Rev. Immunol. 23:161-196.
35. Heikenwalder, M., M. Polymenidou, T. Junt, C. Sigurdson, H. Wagner, S. Akira, R. Zinkernagel, and A. Aguzzi. 2004. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10:187-192.
36. Barry, M., and R.C. Bleackley. 2002. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2:401-409.
37. Suk, K., S. Kim, Y.H. Kim, K.A. Kim, I. Chang, H. Yagita, M. Shong, and M.S. Lee. 2001. IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J. Immunol. 166:4481-4489.
38. Engwerda, C.R., M. Ato, S.E. Cotterell, T.L. Mynott, A. Tschannerl, P.M. Gorak-Stolinska, and P.M. Kaye. 2002. A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am. J. Pathol. 161:429-437.
39. Ato, M., H. Nakano, T. Kakiuchi, and P.M. Kaye. 2004. Localization of marginal zone macrophages is regulated by C-C chemokine ligands 21/19. J. Immunol. 173:4815-4820.
40. Nolte, M.A., R. Arens, M. Kraus, M.H. van Oers, G. Kraal, R.A. van Lier, and R.E. Mebius. 2004. B cells are crucial for both development and maintenance of the splenic marginal zone. J. Immunol. 172:3620-3627.
41. Lu, T.T., and J.G. Cyster. 2002. Integrin-mediated long-term B cell retention in the splenic marginal zone. Science. 297:409-412.
42. Karlsson, M.C., R. Guinamard, S. Bolland, M. Sankala, R.M. Steinman, and J.V. Ravetch. 2003. Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J. Exp. Med. 198:333-340.
43. Kawamoto, H., K. Sakaguchi, A. Takaki, S. Ogawa, and T. Tsuji. 1993. Autoimmune responses as assessed by hypergammaglobulinemia and the presence of autoantibodies in patients with chronic hepatitis C. Acta Med. Okayama. 47:305-310.
44. Kwong, P.D., M.L. Doyle, D.J. Casper, C. Cicala, S.A. Leavitt, S. Majeed, T.D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 420:678-682.
45. Haynes, B.F., J. Fleming, E.W. St Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R.M. Scearce, K. Plonk, H.F. Staats, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 308:1906-1908.
46. Wilkins, B.S., Z. Davis, S.B. Lucas, G. Delsol, and D.B. Jones. 2003. Splenic marginal zone atrophy and progressive CD8+ T-cell lymphocytosis in HIV infection: a study of adult post-mortem spleens from Cote d'Ivoire. Histopathology. 42:173-185.
47. Hendriks, J., L.A. Gravestein, K. Tesselaar, R.A. van Lier, T.N. Schumacher, and J. Borst. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1:433-440.
48. Oxenius, A., M.F. Bachmann, R.M. Zinkernagel, and H. Hengartner. 1998. Virus-specific MHC class II-restricted TCR-transgenic mice: effects on humoral and cellular immune response after viral infection. Eur. J. Immunol. 28:390-400.
49. Pircher, H., K. Bürki, R. Lang, H. Hengartner, and R.M. Zinkernagel. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature. 342:559-561.
50. Chen, J., M. Trounstine, F.W. Alt, F. Young, C. Kurahara, J.F. Loring, and D. Huszar. 1993. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int. Immunol. 5:647-656.
51. Marino, M.W., A. Dunn, D. Grail, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. Moore, B. Williamson, et al. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA. 94:8093-8098.
52. Battegay, M., S. Cooper, A. Althage, J. Baenziger, H. Hengartner, and R.M. Zinkernagel. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J. Virol. Methods. 33:191-198.